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mAbs, depending on their isotype. Both CD3 mAbs of the IgG2a and IgA class induce a rapid depletion of lymphocytes from the peripheral blood compart ment, but lymphocytopenia after IgG2a CD3 mAb is persistent, whereas lymphocytopenia after IgA CD3 mAb is quickly reversed.1"3 Because both IgG2a CD3 mAb and IgA CD3 mAb induce an immediate transient activation and up-regulation of adhesion molecules in vitro, paralleled by transient adhesion of T cells to a monolayer of vascular endothelial cells, we postulated that the mechanism of disap pearance of T cells from the peripheral blood com partment might be the binding of these cells to the endothelium of the peripheral lymphoid organs. 4 The persistence of peripheral lymphocytopenia, then, might be mediated by at least two other, pos sibly cooperating, mechanisms: (1) opsonisation of T cells by CD3 mAb and complement, with seques tration of these cells in the mononuclear phagocyte system by means of binding to Fc and complement receptors; (2 ) up-regulation of the adhesion mole cules VCAM-1 and ICAM -1 on the endothelium induced by cytokines such as tumor necrosis factor-a and interferon 7 , which are known to be re leased after the administration of CD3 mAb of the IgG2a class.5,6 The latter leads to increased adhe siveness of endothelium to the counterstructures present on peripheral blood lymphocytes.7"10 The murine IgA isotype switch variant CD3 mAb does not bind to human Fc receptors, does not activate lymphocytes, and hardly results in the release of cytokines. Moreover, monomeric murine IgA is gen erally assumed to have poor activating capacity for human complement. 2, 11 This may explain why ad ministration of this mAb in vivo induces a rapid lymphocytopenia that is transient.
Recently it was shown that a murine CD3/TCR mAb of the IgG l isotype (i.e., WT31) induces a long-lasting T lymphocytopenia comparable to that observed after CD3 mAb of the IgG2a class only in 70% of the patient population. 12, 13 This may be explained by polymorphism of Fc^RIIa, the human Fc receptor for murine IgG l, of which two allelic forms exist. They have been classified as Fc7 RIIa-H131 and F c^R IIa-R D l, according to their binding capacity to murine Ig G l.14 Seventy percent of the human population carries the Fc7RIIa-R131 form (high responders), whereas the other 30% of the population bears the Fc7RIIa-H131 form (low re sponders) . 15 The administration of WT31 to pa tients of the high-responder phenotype induces T cell proliferation, cytokine release, and the occur rence of adverse effects. In contrast, in low-responder patients, W T31 does not induce the release of cytokines, does not lead to adverse effects in vivo, and does not stimulate lymphocytes in vitro. 13,15'16 However, it is not clear whether WT31 can activate or up-regulate the expression of adhesion molecules on lymphocytes and endothelium, as can CD3 mAbs of the IgG2a or IgA class, nor whether it can fix complement, as can IgG2a CD3 mAb.
To elucidate the role of C D lla/C D 18 and C D llb/C D 18 and Fc receptor binding in the patho genesis of lymphocytopenia, CD3/TCR mAbs of three different isotypes were tested on their capacity to activate or up-regulate expression of adhesion molecules on T lymphocytes in vitro and their ca pacity to induce adhesion of these T cells to endo thelial cell monolayers. Blocking experiments were performed to study which adhesion molecule(s) are involved. In addition, clinical findings were corre lated to our in vitro results.
METHODS

Patients.
In 20 kidney transplant recipients who were treated prophylactic ally with either the IgG2a (lX2a) or the IgA (1XA) switch variant CD3 mAb-which was ad ministered twice daily, 0.5 mg intravenously for 10 daysperipheral lymphocyte counts were determined immedi ately before the first administration of CD3 mAb and at 15 minutes, 30 minutes, and 1, 3, and 6 hours thereafter.2
The first dose was preceded by 500 mg methylprednisolone and 25 mg promethazine, administered 1 hour before the CD3 mAh.
In addition, the number of lymphocytes in time was measured after the first administration of WT31 in 6 renal transplant recipients with acute rejection, 13 The antibody had been purified at the Dutch National Institute of Pub lic Health and Environmental Protection.17 Three of these patients were high responders and 3 were low responders, as determined by in vitro T cell proliferation induced by WT31.15 Each of the 3 low responders and the first treated high responder received an initial intravenous dose of 6 mg WT31, whereas in the other two high re sponders an initial dose of 1 mg was given. In 1 out of 3 low-responder and 2 out of 3 high-responder patients, the first WT31 dose was preceded by 50 mg prednisone, whereas the other patients did not receive any premedi cation.
Healthy control individuals. In 20 healthy control indi viduals the phenotype of Fc-yRIIa was determined on granulocytes and monocytes by indirect immunofluores cence. 18 The mAbs used to discriminate Fc7RIIa-H131 and Fc7RIIa-R131 donors were IV.3 (Medarex, Lebanon, N.H.), which bind both allotypic forms of Fc^RIIa, and 41H16 (provided by Dr. B. M. Longenecker, Edmonton, Alberta, Canada), which selectively recognizes the Feylla-R131 allotype.19,20 FITC-labeled F(ab')2 fragments of goat anti-mouse immunoglobulin (G26M17F, CLB, Am sterdam, the Netherlands) were used as secondary anti-body. All incubations for phenotypic analysis were per formed in the presence of 20% (vol/vol) heat-inactivated (30 minutes at 56° C) human serum to avoid cytophilic binding of mouse mAbs. Fluorescence was quantitated with the flow cytometer (FACScan; Becton Dickinson, Mountain View, Calif.). To confirm Fc7RIIa-H131 and Fc7RIIa-R131 phenotypes, mononuclear cells were also tested in a T cell proliferation assay, with murine IgGl and human IgG2 anti-CD3 mAbs used as stimulants. 15, 18 From these healthy control individuals 6 high responders and 6 low responders were selected, and peripheral blood was taken for in vitro studies.
Lymphocyte counts. Total leukocyte and differential counts were determined by flow cytometry (Technicon HI system; Bayer/Technicon, Tarrytown, N.Y.) in blood an ticoagulated with ethylenediaminetetraacetic acid.
In vitro studies: Adhesion molecule expression. Heparinized peripheral blood samples from 12 healthy individ uals, 6 high responders and 6 low responders, were put in a waterbath of 37° C. A 5 ml sample was kept apart, and the remaining blood was divided into multiple aliquots, which were each incubated with one of the following mAbs in different concentrations: the murine isotype switch variant CD3 mAbs lX2a (IgG2a iso type) and 1XA (IgA isotype), the murine TCR mAb WT31 (IgGl iso type), and the following irrelevant murine isotype control antibodies: F23-49 (mouse IgG2a, directed against Myco bacterium tuberculosis),21 TEPC15 (mouse IgAw, myeloma protein; Sigma, St. Louis, Mo.), or CLB-M1451 (mouse IgGl, directed against plant allergens; CLB). To study whether the effects on expression of adhesion molecules were specific for antibodies directed to the CD3/TCR complex, the same experiments were also performed with murine IgG2a mAbs directed against cither the CD4 mol ecule (CLB-T4) or against a MHC class I antigen (W6/ 32). At 3, 30, and 60 minutes after addition of the mAbs, whole blood samples were taken. PBMCs were obtained by centrifugation of heparinized blood on Ficoll-Paque (density 1.076; Pharmacia, Uppsala, Sweden). Contami nating erythrocytes were lysed by incubation with NH4CI for 10 minutes on ice, followed by 2 x washing of the PBMCs in PBS containing 0.5% wt/vol bovine serum al bumin and 0.01% wt/vol sodium azide. The PBMCs were incubated for 30 minutes at 0° C in PBS containing 0.5% wt/vol bovine serum albumin and 0.01% wt/vol sodium azide with appropriate dilutions of the mAb CDlla-FITC (Dako; clone MHM24,IgGlk), [NKI-L16]-FITC, which recognizes a Ca2l'-dependent epitope on the CD1 la/ CD 18 complex that is expressed only on activation of the complex22,23 or CDllb-PE (Dako; clone 2LPM19c,IgGlk). In addition, part of the cells was incu bated with the biotinylated mAb LECAM-1 (directed against L selectin, clone SK11, IgG2a; Becton Dickinson), followed by incubation with PE-labeled streptavidin (Bec ton Dickinson). Next, we performed two-color staining of these samples with a CD3 mAb to determine the total number of T cells. Because two-color staining with a FITC or PE-labeled detecting CD3 mAb might be hampered by the in vitro bound CD3/TCR mAb, before these experi ments we studied which detecting CD3 mAb could be used for optimal detection of T cells without causing interference with the already bound CD3/TCR mAb. In the case of WT31, at any concentration tested, two-color staining was possible with CD3-PE or CD3-FITC (both from Becton Dickinson; Leu-4; clone SK7, IgGl). In ex periments with lX2a and 1XA, two-color staining was optimal when using a mixture of directly labeled CD4 and CD8 mAb. In control experiments, the mixture of these CD4 and CD8 mAbs (Becton Dickinson; Leu-3 a; clone SK3, IgGl and Leu-2a; clone SKI, IgGl, respectively) was shown to detect numbers of T cells equal to the number detected by the Leu-4 mAb. Determination of the total number of CD3+ cells was performed by a direct labeling procedure with Leu-4-FITC (Becton Dickinson).
The same experiments were performed on PBMCs in cubated with CD3/TCR mAbs after their isolation from whole blood by Ficoll density gradient centrifugation.
Analysis of cell suspensions was done on FACScan (Becton Dickinson). Lymphocytes in the PBMC popula tion were gated on forward and sideward scatter.
Functional adhesion studies. Functional adhesion stud ies were performed in parallel with the above-described assays. PBMCs from the same 12 healthy control individ uals were washed 3 times in Tris-buffered Earle's bal anced salt solution containing 5% FCS. CD3+ cells were obtained as follows: B lymphocytes, monocytes, and nat ural killer cells were removed by incubation with murine mAb anti-CD19 (CLB, clone 11G1), anti-CD14 (CLB, clone 8G3), and anti-CD16 (CLB, gran-1) followed by incubation with sheep-anti-mouse IgG-coated Dynabeads (N-0212; Dynal A.S., Oslo, Norway). This procedure re sulted in >95% pure CD3+ cell populations, as was con firmed by FACS analysis after staining with FITC-labeled CD3-and PE-iabeled CD16 and CD56 mAbs (NK-Simulset; Becton Dickinson). CDV cells were resuspended and adjusted to a concentration of 2 x 106 cells/ml and incu bated on ice for 30 minutes with either lX2a, tXA, WT31, CLB-T4, W6/32, or the irrelevant isotype control antibod ies F23-49, TEPC15, and CLB-M1451 in the indicated concentrations. Phorbol myristate acetate PMA, 50 ng/ml (Sigma), was used as a positive control. Next, the cells were washed 2 times at 4° C with Iscove's modified Duibecco's medium containing 5% FCS. Because cross-link ing is assumed to occur in vivo after the administration of CD3 mAb of the IgG2a class and after administration of WT31 to patients with the high-responder phenotype, adhesion studies were also performed after cross-linking of the mAb-coated CD3/TCR complex with goat-antimouse Ig. Therefore, after incubation with the T cell mAb, one half of the cell suspension was cross-linked by 2 lig/ml goat anti-mouse Ig (GM17D, CLB), immediately followed by 3 minutes of 10 g centrifugation at 37° C; no goat-anti-mouse Ig was added to the other half 24 Then 25 jxl of these cell suspensions was added to a monolayer of an immortalized endothelial cell line, which is derived from human umbilical vein endothelial cells, 25 and was cultured in 96-well plates (Nunclon Micro Well F96; Nunc A.S., Roskilde, Denmark) on 1% gelatin (G1890; Sigma) in PBS. The remaining part of the cell suspensions was put in a shaking waterbath at 37° C, from which samples were added to endothelial cell monolayers after 30 and 60 minutes. The 96-well plates were incubated for 15 minutes at 37° C (5% C02). Then the nonadherent fraction was removed by washing three times with 200 jxl of 37° C Earle's balanced salt solution containing 5% FCS. The adherent fraction was stained with Diff-Quick (i.e., a three-step staining set consisting of [1] fixation in metha nol with fast green, 0.002 gm/L; [2] eosin G in phosphate buffer, pH 6.6; and [3] thiazine dye in phosphate buffer, pH 6.6 [Baxter Dade A.G, Diidingen, Switzerland]). All experiments were performed in triplicate.
Blocking studies were performed with mAbs directed against either the common ß2 integrin chain (CD 18: TS 1/18,26 against CD lia [NKI-L7]27 or against CDllb [Bear-1]28) in a final concentration of 10 fJLg/mi, which was added to the endothelial cell monolayer simultaneously with the T cells that had been incubated with the different CD3/TCR mAbs for 3 minutes at 37° C. This concentra tion of 1.0 (xg/ml had shown in previous studies to result in a maximal inhibition of adhesion.
The adhesion was scored blindly by 3 technicians inde pendently in a semiquantitative way (score ranging from 0 to 5; 0 = no T cells adherent to endothelium; 1 = <50 T cells/field; 2 -50 to 100 T cells/field; 3 = 100 to 250 T cells/field; 4 = 250 to 350 T cells/field; 5 = >350 T cells/field; scored at a magnification of X200).
With therapeutic plasma levels considered to be about 1 fig/ml , the studies on expression of lymphocyte adhesion molecules as well as the adhesion studies were performed with different concentrations of the mAb, as follows: for WT31, 0.01, 0.1,1 and 10 jjug/ml; for lX2a and 1XA, 0.01, 0.1, 1 and 5 jxg/ml. T cell binding studies. Differences between the three T cell mAbs in their binding to T cells might influence the degree of activation or up-regulation of adhesion molecules. Therefore, the T cell binding of the three mAbs was analyzed as follows: PBMCs from 4 healthy control individuals were isolated by Ficoll-density gradient cen trifugation and incubated for 30 minutes on ice with lX2a, 1XA, WT31, or the irrelevant murine isotype control antibodies in a concentration ranging from 0 to 4 [lg/ml. The cells were washed, and subsequently PElabeled rabbit F(ab')2 anti-mouse Ig was added (code R 0439; Dako, Glostrup, Denmark) at multiple dilutions ranging from 1:5 to 1:160. After 30 minutes of incuba tion on ice, the cells were washed and the MFI was measured by FACS analysis with a gate to identify the lymphocyte fraction. Because binding of the detecting rabbit F(ab')2 anti-mouse I g may be different for the diverse murine isotype mAbs, the actual measured MFI values cannot be compared. Therefore, the concentra tion of T cell mAb that was needed to reach a 50% value of the maximal level in MFI was used as a mea sure for T cell binding.
Complement studies. The ability of each of the three T cell mAbs to induce binding of C3 activation products on T cells was determined by FACS analysis. Heparinized whole blood samples from 6 healthy high-responder and 6 healthy low-responder control individuals were incubated for 15 minutes at 37° C with 1 |ig/ml lX2a, 1XA, WT31, or the irrelevant murine isotype control antibodies. Mono nuclear cells were isolated by centrifugation on Ficollpaque. Deposition of C3 activation products on T cells was detected with a biotinylated mAb directed against a neo-epitope on C3b, C3bi, and C3c (C3-28, CLB29), fol lowed by a second incubation step with PE-labeled streptavidin and a third incubation with a FITC-labeled CD 3 mAb (Leu-4; Becton Dickinson).
Calculations and statistical analysis
Absolute number of double-positive cells. The percentage of double-positive cells was calculated by means of PCLYSYS software from Becton Dickinson and was multiplied times the absolute number of lymphocytes at the same time point, resulting in the absolute number of double-positive cells. All values are expressed as mean ± SEM.
MFI measurements. At all time points the MFI was calculated with PCLYSYS software. All values are ex pressed as mean ± SEM.
RESULTS
Lymphocytopenia after in vivo administration of differ ent CD3/T ceil mAbs. Administration of either lX 2a or 1XA induced a disappearance of virtually all T lym phocytes from the peripheral blood compartment within 15 minutes. However, CD3 depletion after 1XA was of shorter duration than that after lX2a administration; whereas at least during the first 2 days of IgG2a treatment the number of CD3+ cells remained low as compared with pretreatment val ues, lXA-induced T cell depletion lasted for several hours only.1,2 After administration of the IgGl TCR mAb WT31, the occurrence of a peripheral lympho cytopenia appeared to be dependent on the Fey receptor Ila status of the patient receiving WT31. Also, in high-responder patients an immediate and long-lasting disappearance of lymphocytes was ob served after the administration of WT31, whereas in low-responder patients the number of peripheral blood lymphocytes remained unchanged (data not shown). On the basis of these results, two phases with different underlying pathogenetic mechanisms can be distinguished in the CD3/TCR mAb-induced periph eral T lymphocytopenia: (1) an immediate decline in the number of peripheral T lymphocytes and (2) per sistence of the peripheral lymphocytopenia. lX 2a or 1XA to whole blood induced an immediate increase in the number of T cells bearing the acti vated form of CDlla/CD18, as detected by NKI-L16 expression, and an up-regulation of the C D llb / CD18 molecule ( Fig. 1 ). m A b s d i r e c t e d a g a i n s t t h e TCR. Incubation of whole blood from 6 healthy high responders with 1 jxg/m l WT31 induced an immediate increase in the number of NKI-L16-positive T cells. In contrast, no change was observed after the addition of WT31 to whole blood from 6 healthy low responders (Fig. 1,  A ) . No changes in CD 'llb expression were observed, either in the high responders or in the low respond ers, while the addition of 1 jjig/ml lX 2a or 1XA in the same experiments did induce an increase in C D llb expression ( Fig* 1, B) . No effects on Lselectin expression, either in percentage of positive cells or in mean fluorescence intensity, were ob served on CD3+ T cells after the addition of either 1XA, lX2a, or WT31. Incubation of whole blood with 1 |Ag/ml of the irrelevant murine mAbs of the IgG2a, IgA, or IgG l isotype did not alter the ex pression of NKI-L16 or C D llb (Fig. 1, A and B ) , nor did incubation with the CD4 or the M HC class I mAb (data not shown). Dose-response studies showed a maximal effect on NKI-L16 and C D llb expression at a concentration of 1 jjig/ml for lX 2a or 1XA. Regarding WT31, increasing the concentra tion to 10 p,g/ml had only a small additional effect on NKKL16 expression in high responders but did not affect the NKI-L16 expression in low respond ers, Even at this high concentration of WT31, no changes in C D llb expression were observed in high responders or low responders (data not shown). W hen similar experiments were performed on PBMCs instead of whole blood, the same results were obtained (data not shown).
In vitro effects of CD3/TCR mAbs
Expression of adhesion molecules in vitro
Functional adhesion studies. Purified T cells from each of the 12 healthy control individuals showed an immediate adhesion to endothelial cell monolayers after incubation for 3 minutes with 1 |xg/ml lX 2a or 1XA (Fig. 2) . For WT31, a discrimination could be made between high responders and low responders: in high responders, incubation with 1 |xg/ml WT31 also induced adhesion of T cells to endothelium, whereas no T cell adhesion could be detected in the low-responder group, when adhesion was studied without cross-linking (Fig. 2) . The irrelevant murine isotype control antibodies, the CD4, or the MHC class I mAbs also did not affect adhesion of T cells to endothelial cell monolayers (not shown). Incuba tion with 50 ng/ml phorbol myristate acetate, used as a positive control, resulted in an adhesion score of 3.75 ± 0,22 after 3 minutes. Dose-response curves showed that the T cell mAb-induced adhesion was dose dependent. A maximal adhesion was observed with 1 |ULg/ml of each of the three mAbs tested. For WT31, increasing the dose to 10 jjLg/ml still did not result in adhesion of T cells to endothelial cell monolayers in the low-responder group. Adhesion blocking studies showed that coincubation with ei ther a C D lla or a CD18 mAb completely inhibited the adhesion observed after 3 minutes of incubation with either lX 2a, 1XA, or WT31. However, coincu bation with a C D llb mAb resulted in partial inhi bition of the CD3 mAb-induced adhesion but did not suppress the WT31-induced adhesion (Fig. 2) . Studies in which incubation with the T cell mAb was followed by cross-linking with goat-anti-mouse Ig showed that with each of the three mAbs, subse quent cross-linking resulted in higher adhesion scores as compared with preincubation with the same m Ab w ithout cross-linking. A fter cross-linking, adhesion was also induced by WT31 in the low responders (data not shown). For the CD3 mAbs lX 2 a and 1XA, adhesion was maximal after 3 m inutes of cross-linking at 37° C, followed by a decrease. F o r WT31, maximal adhesion was ob served after 30 minutes of cross-linking, both in high responders and in low responders (data not shown). T cell binding studies. Fig. 3 shows a difference in T cell binding between the CD3 mAbs lX2a and 1XA on the one hand and WT31 on the other hand. When an optimal dilution (1:10) of the detecting PE-labeled rabbit F(ab')2 anti-mouse Ig conjugate was used, for the CD3 mAbs lX2a and 1XA a 50% value of the maximal MFI could already be reached at concentrations of 41.5 and 76.5 ng/ml, respec tively, whereas for WT31 a higher concentration (585 ng/ml) was needed. This suggests that WT31 has a lower affinity for binding to the CD3/TCR complex than do the switch variant CD3 mAbs lX2a and 1XA.
Complement activation. Fixation of C3 activation products on T cells could be observed only after incubation of whole blood with the IgG2a mAb lX2a, not after incubation with the IgA switch vari ant 1XA or the IgG l TCR mAb WT31 (Fig. 4 ). Increasing the 1XA or WT31 dose to 10 jxg/ml still could not induce any fixation of C3 activation prod ucts on T cells. No differences were observed be tween high responders and low responders concern ing the ability to induce deposition of C3 activation products on T cells (not shown).
DISCUSSION
To interpret the CD3/TCR niAb-induced lym phocytopenia in our different patient groups, the preadministered corticosteroid dose has to be taken into account. To diminish first-dose side effects, the first administration of CD3/TCR mAb is generally preceded by the administration of a single dose of corticosteroids, which are known to induce a revers ible peripheral lymphocytopenia by themselves. 30, 31 This lymphocytopenia starts 30 minutes after corti costeroid administration and reaches its maximum effect in about 6 hours. 30, 31 For this reason it is unlikely that corticosteroids have something to do with the immediate decline in peripheral T lympho cytes after CD3/TCR mAb administration. How ever, persistence of the lymphocytopenia might be modified by corticosteroids. In chimpanzees, admin istration of the IgA switch variant CD3 mAb without corticosteroid premedication induced a clear saw- tooth curve with respect to the number of T cells: a very fast decline and an almost complete recovery within 24 hours.1 This effect is also visible in human subjects on day 8 of the treatment with the IgA switch variant mAb CD3. On day 1 the recovery is partial but clearly present, and is apparently modi fied by pretreatment with high-dose corticoste roids.2 For the reasons mentioned we feel it justified to discuss patterns of CD3 lymphocytopenia even after corticosteroid administration. Theoretically, three mechanisms may be involved in the CD3/TCR mAb-induced disappearance of T lymphocytes from the peripheral blood compart ment: (1) activation up-regulation (or both) of ad hesion molecules on lymphocytes resulting in adhe sion to vascular endothelium; (2) Fc-Fc receptor interaction with activation of mononuclear cells re sulting in systemic cytokine release and leading to up-regulation of adhesion molecules on vascular en dothelium; (3) interaction of the Fc part of the mAb with an appropriate Fc receptor or coating of T cells by complement activation products (or both inter action and coating), giving rise to sequestration of the cells in the mononuclear phagocyte system, eventually followed by lysis of these cells. However, in a previous article we presented arguments that make it unlikely that cell lysis is a major mechanism in the observed lymphocytopenia. 32 On account of the observations in vivo, two phases can be discerned in the peripheral lympho cytopenia after CD3/TCR mAb, and these may have different underlying pathogenetic mechanisms (summarized in Table I ). For antibodies that induce an immediate decline in the number of T lympho cytes, the common denominator is that they induce both activation and an increase in expression of adhesion molecules in vitro. CD3 mAbs of either the IgG2a or the IgA isotype were able to induce a transient adhesion of T cells to endothelial cells, and this could completely be blocked by either a C D lla or CD18 mAb and partially by a C D llb mAb. Therefore, activation of the CDlla/CD18 molecule seems to be a prerequisite for the CD3 mAb-in duced T cell adhesion to endothelium, but increased expression of C D llb may be needed for optimal CD3 mAb-induced adhesion. WT31 could induce adhesion of T cells from high responders to endo thelium without apparent involvement of C D llb. Because administration of WT31 in vivo to high responders is able to induce an immediate periph eral T cell lymphocytopenia, we conclude that upregulation of the CDllb/CD18 molecule is not es sential for the induction of such a peripheral T lymphocytopenia. In low responders, the WT31 mAb appeared to induce neither activation nor upregulation of adhesion molecules on T cells. In agreement with this observation, no immediate pe ripheral lymphocytopenia was observed after WT31 administration to low responder patients. The difference in ability to induce an up-regula tion of C D llb between CD3 mAbs and the TCR mAb WT31 is difficult to explain. Because each of the studied mAbs binds to the CD3/TCR complex, a difference in intracellular signal transduction is un likely to be responsible. The lower affinity of WT31 as compared with that of the CD3 mAb for their respective ligands may play a role in the observed differences, although other yet-unknown factors may be involved as well. In vivo up-regulation of C D llb/C D 18 probably results from a direct signal ing pathway that is initiated by binding of CD3/TCR mAbs to the CD3/TCR molecule and leads to stim ulation of the inositol phospholipid metabolism, thereby giving rise to activation of protein kinase C and Ca2+ fluxes, which in turn may lead to up-regulation of CDllb/CD18 expression on T cells.33,34 Although 1XA is a nonactivating mAb, it is able to induce Ca2+ mobilization in peripheral blood T lymphocytes,35 which may be involved in the observed activation of CDlla/CD18 and increased expression of CDllb/CD18.
Expression of adhesion molecules
Number of MFI of (NKI-L16)+ C D llb on T cells T cells
The common denominator for antibodies that in duce persistence of peripheral lymphocytopenia is interaction of the Fc part of the mAb with an ap propriate Fc receptor. Indeed, persistence is not observed after administration of 1XA to all patients or WT31 to low responders, corresponding with the absence of an appropriate Fc receptor for these mAbs. Various mechanisms may be responsible for the Fc receptor-mediated decline in peripheral T lymphocytes. Binding of the Fc part of the mAb to its Fc receptor can lead to sequestration of lympho cytes in the mononuclear phagocyte system. In ad dition, interaction of the Fc part of the CD3/TCR mAb on T cells with its Fc receptor on mononuclear cells induces activation of the latter, resulting in the release of cytokines such as tumor necrosis factor-a and interferon-7 . Indeed, a systemic cytokine re lease has been observed after the administration of IgG2a CD3 mAb or WT31 to high responders, whereas only a minimal amount of tumor necrosis factor-a was observed after WT31 administration to low responders or after the administration of 1XA 2,5,6, 13 These cytokines have been shown to induce an up-regulation of ICAM-1 and VCAM-1 on the vascular endothelium in vitro, resulting in in creased adherence of T cells to endothelium.7,8'36 Be cause WT31 does not induce any complement activa tion and persistence of the lymphocytopenia is still observed after the administration of this mAb to highresponder patients, it seems justified to conclude that complement activation is certainly not an essential mechanism for this efect to occur. Whether activation of the complement system only would be sufficient for persistence of lymphocytopenia cannot be concluded from the current experiments.
In conclusion, two different phases can be distin guished in the CD3/TCR-induced T lymphocytope nia. The first phase of immediate disappearance can be explained by activation or increased expression (or both) of adhesion molecules. This seems to be sufficient to induce an immediate decline in periph eral T cells in vivo. The second phase of persistence of the peripheral lymphocytopenia is directly depen dent on the heavy chain of the mAb and the pres ence of an appropriate Fc receptor for this mAb.
